

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2021/257841 A9

(43) International Publication Date
23 December 2021 (23.12.2021)

WIPO | PCT

(51) International Patent Classification:

A61K 39/215 (2006.01) C07K 14/165 (2006.01)
C07K 14/135 (2006.01)

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(21) International Application Number:

PCT/US2021/037846

(48) Date of publication of this corrected version:

24 February 2022 (24.02.2022)

(22) International Filing Date:

17 June 2021 (17.06.2021)

(15) Information about Correction:

see Notice of 24 February 2022 (24.02.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/040,193	17 June 2020 (17.06.2020)	US
63/160,445	12 March 2021 (12.03.2021)	US
63/194,092	27 May 2021 (27.05.2021)	US

(71) Applicant: **MEISSA VACCINES, INC.** [US/US]; 1100
Island Drive, Suite 202, Redwood City, CA 94065 (US).

(72) Inventors: **MOORE, Martin**; 20 Gateway Court, San Carlos, CA 94070 (US). **JORDAN, Robert**; 1005 Lido Lane, Foster City, CA 94404 (US). **TIONI, Mariana**; 728 Serena Drive, Pacifica, CA 94044 (US).

(74) Agent: **GUSTAFSON, Megan, A.** et al.; Goodwin Procter LLP, 100 Northern Avenue, IP Docketing Dept./7th FL, Boston, MA 02210 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: CHIMERIC RSV AND CORONAVIRUS PROTEINS, IMMUNOGENIC COMPOSITIONS, AND METHODS OF USE

(57) Abstract: The invention relates generally to chimeric viral fusion proteins comprising the ectodomain and optionally the trans-membrane domain of a first viral fusion protein (e.g., a spike protein of a coronavirus) and the cytoplasmic domain of a second viral fusion protein (e.g. RSV), immunogenic compositions comprising such chimeric proteins, and methods of use of same.

WO 2021/257841 A9